HBOT Contraindications: When It's Genuinely Dangerous

Last updated: April 2026

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before starting any treatment.

Affiliate Disclosure: We may earn a commission when you purchase through our links. This does not affect our editorial independence.

Quick Answer

The only absolute contraindication to hyperbaric oxygen therapy (HBOT) is an untreated pneumothorax, which can precipitate a life-threatening tension pneumothorax once chamber pressure changes StatPearls HBOT Contraindications.
High doses of HBOT can lead to severe, but reversible, emotional symptom exacerbation in 30-39% of subjects being treated for PTSD, according to a 2024 systematic review HBOT efficacy in PTSD 2024 systematic review.
The FDA updated its cleared-use list in 2025-2026 to add sudden idiopathic hearing loss and sudden painless vision loss (from central retinal artery occlusion), bringing the total to 14 approved conditions FDA Safe Use HBOT Devices.
Clinic pricing in 2026 ranges from $200 to $600 per soft-chamber session, while hospital-based medical HBOT can exceed $2,000 per session; Medicare Part B covers roughly 80% of the approved amount for on-label indications, after a $283 Part B deductible Hyperbaric Oxygen Therapy Cost 2026.
HBOT has not shown statistically significant differences in NIHSS score or Barthel index for acute ischemic stroke patients compared to control groups in a 2024 meta-analysis, while adverse event incidence at the end of HBOT treatment was lower in the HBOT group (OR = 0.42, 95%CI = 0.19 to 0.94).
Research is ongoing for HBOT in conditions like traumatic brain injury, anchored by the $28 million USF Health state-funded trial for Florida service members and veterans with TBI USF Health HBOT TBI Trial and the federal NCT02407028 study ClinicalTrials.gov HBOT Brain Injury Treatment Trial.

Hyperbaric oxygen therapy (HBOT) involves breathing pure oxygen in a pressurized chamber. While it offers potential benefits for certain conditions, it is crucial to understand when this treatment might pose genuine dangers. Our 2026 analysis pulls together the latest FDA safety guidance, newly cleared indications, and current-year pricing, along with recent systematic reviews and meta-analyses that continue to define the risk profile. At the top of the danger list sits a single absolute contraindication, untreated pneumothorax, because any ambient pressure change inside the chamber can convert a simple pneumothorax into a tension pneumothorax that compromises circulation within minutes. Beyond that single absolute bar, relative contraindications stack up quickly: uncontrolled asthma and severe COPD (pulmonary barotrauma and hypercarbia risk), recent ear or thoracic surgery, claustrophobia, uncontrolled seizure disorders, and concurrent chemotherapy with doxorubicin, cisplatin, or bleomycin, where hyperoxia amplifies pulmonary and cardiac toxicity. For patients undergoing HBOT for posttraumatic stress disorder (PTSD), the highest oxygen doses can lead to a severe, but reversible, worsening of emotional symptoms in 30-39% of individuals, as detailed in a 2024 systematic review. This significant percentage underscores the importance of careful dosage management and patient monitoring. In contrast, for acute ischemic stroke patients, a 2024 meta-analysis found no statistically significant differences in key outcomes like NIHSS score or Barthel index, suggesting HBOT may not offer significant benefits in these specific areas, though adverse event incidence at the end of treatment was found to be lower with HBOT (OR = 0.42, 95%CI = 0.19 to 0.94). Understanding these specific risks and the contexts in which they arise is essential for anyone considering HBOT in 2026. See the stroke recovery evidence atlas for the full investigational evidence breakdown.

What are the primary risks of HBOT?

The primary risks associated with hyperbaric oxygen therapy (HBOT) are often dose-dependent and vary based on the treated condition. One significant risk identified in recent research involves the potential for severe emotional symptom exacerbation, particularly when high cumulative oxygen doses are administered. This effect was observed in studies focusing on posttraumatic stress disorder (PTSD). Specifically, 30-39% of subjects experienced a severe yet reversible worsening of emotional symptoms when exposed to the highest oxygen doses during their HBOT treatment for PTSD HBOT efficacy in PTSD 2024 systematic review. This finding is critical because it points to a specific threshold or level of oxygen exposure that can trigger an adverse emotional response in a notable portion of the patient population. These emotional exacerbations, while severe, were described as reversible, meaning they subsided over time once the treatment protocol was adjusted or completed.

Beyond these specific emotional responses, other side effects reported in PTSD studies were generally transient and minor. This suggests that while emotional sensitivity to high oxygen doses is a distinct concern, many other potential side effects of HBOT, such as ear discomfort or sinus issues, are typically not severe or long-lasting. The overall safety profile, when considering these minor and transient side effects, appears favorable. However, the unique risk of emotional symptom exacerbation at high doses warrants careful consideration and patient selection, especially for individuals with pre-existing psychological vulnerabilities or conditions like PTSD. Practitioners must be acutely aware of this potential adverse reaction and be prepared to monitor for and manage such symptoms during treatment.

When we consider HBOT in the context of acute ischemic stroke, the safety profile appears somewhat different. A meta-analysis published in 2024 evaluated the efficacy and safety of HBOT as an adjunctive therapy for acute ischemic stroke. This analysis included eight studies with a total of 493 patients. The findings indicated that the incidence of adverse events at the end of treatment was actually lower in the HBOT group compared to the control group. Specifically, the odds ratio (OR) for adverse event incidence at the end of treatment was 0.42 (95% CI = 0.19 to 0.94) for HBOT patients compared to controls. This suggests that, for acute ischemic stroke, HBOT might even contribute to a reduction in certain adverse events during the immediate treatment period. However, it is important to note that this particular study also found no statistically significant differences in adverse event incidence within ≤ 6 months of follow-up (OR = 0.98, 95% CI = 0.25 to 3.79), indicating that any initial reduction in adverse events might not persist long-term.

The difference in observed risks between PTSD treatment and acute ischemic stroke treatment highlights the condition-specific nature of HBOT safety. For PTSD, the concern lies in the psychological impact of high oxygen doses, leading to emotional distress in a significant minority of patients. For acute ischemic stroke, the immediate treatment period showed a potentially favorable safety profile regarding adverse events. These distinctions emphasize the need for individualized risk assessment based on the patient's underlying condition, their overall health status, and the specific HBOT protocol being considered.

Understanding Dose-Response in HBOT Risks

The concept of a dose-response relationship is crucial when discussing HBOT risks. For PTSD, the severity of emotional exacerbation was directly linked to the cumulative oxygen dose. This means that as the total amount of oxygen delivered over multiple sessions increased, so did the likelihood and intensity of severe emotional symptoms in a subset of patients. This linear dose-response relationship for increased symptomatic improvement was also noted for overall therapeutic effects, with improvements seen from 1002 to 11,400 atmosphere-minutes of oxygen. However, this therapeutic benefit at higher doses came with the trade-off of increased emotional risk. This underscores the need for a careful balance between achieving therapeutic goals and minimizing potential adverse effects.

Managing Emotional Exacerbation

For patients being treated for PTSD, managing the risk of emotional exacerbation requires a proactive approach. This could involve starting with lower oxygen doses, carefully escalating treatment based on patient tolerance, and closely monitoring psychological state throughout the therapy. The fact that these exacerbations were reversible is reassuring, but it does not diminish the distress they can cause during treatment. Open communication between the patient and the healthcare team is paramount to identify any emerging emotional difficulties promptly and adjust the treatment plan as necessary.

Broader Safety Considerations

While the research specifically points to emotional exacerbation for PTSD and a potentially lower immediate adverse event rate for acute ischemic stroke, other general contraindications and risks of HBOT are well documented. These include barotrauma (injury from pressure changes) to the ears, sinuses, teeth, and lungs; temporary vision changes (typically myopic shifts that resolve in days to weeks after the final session); and, in rare cases, oxygen toxicity affecting the central nervous system and producing seizures. The FDA's most recent safety letter to healthcare providers also flags a heightened fire risk any time high-concentration oxygen is used, which is why UHMS-accredited facilities restrict cotton-only garments, ban personal electronics inside the chamber, and require grounded hardware. The important takeaway from the current research is the specific and statistically significant risk of emotional worsening for PTSD patients at high oxygen doses, and a more neutral or even slightly favorable immediate safety profile for acute ischemic stroke concerning adverse events.

Drug Interactions That Make HBOT Genuinely Dangerous

A frequently underappreciated danger involves drug interactions. Patients undergoing chemotherapy with doxorubicin (Adriamycin) or cisplatin should not receive HBOT during active dosing cycles; hyperoxia amplifies the cardiotoxicity of doxorubicin and the nephrotoxicity and neurotoxicity of cisplatin. Bleomycin carries perhaps the starkest warning: pulmonary fibrosis risk can be triggered months after the last dose, so most protocols require a thorough pulmonary evaluation and, in many cases, a multi-month waiting window before HBOT can proceed. Disulfiram blocks superoxide dismutase and eliminates a key defense against oxygen toxicity, and mafenide acetate (Sulfamylon) causes CO2 retention that interferes with HBOT physiology. Clinics in 2026 are increasingly screening for GLP-1 agonists as well, not because of direct contraindication, but because delayed gastric emptying can complicate pre-session protocols.

When is HBOT considered genuinely dangerous for PTSD patients?

Hyperbaric oxygen therapy (HBOT) is considered genuinely dangerous for posttraumatic stress disorder (PTSD) patients primarily when administered at the highest oxygen doses. While HBOT has shown promise in improving PTSD symptoms, this benefit comes with a significant and specific risk: severe, reversible emotional symptom exacerbation. This adverse reaction was observed in a substantial portion of patients, affecting 30-39% of subjects in studies where the highest oxygen doses were used for PTSD treatment. This specific finding, from a 2024 systematic review, points to a clear threshold where the therapeutic benefits must be carefully weighed against the risk of significant emotional distress.

The systematic review, which included eight studies with a total of 393 subjects, consistently found that while statistically significant symptomatic improvements were achieved for patients, these improvements were often accompanied by this notable side effect at the highest cumulative oxygen doses. The range of effective treatment involved 40-60 HBOT sessions over a wide range of pressures, from 1.3 to 2.0 ATA. Even within this therapeutic range, the higher end of oxygen exposure presented a clear safety concern regarding emotional stability. The linear dose-response relationship for increased symptomatic improvement meant that while more oxygen led to better outcomes, it also increased the risk of severe emotional reactions.

"The greater symptomatic response was accompanied by a greater and severe reversible exacerbation of emotional symptoms at the highest oxygen doses in 30-39% of subjects. Other side effects were transient and minor," stated Susan R Andrews et al. in Front Neurol. 2024. This quote directly highlights the dual nature of HBOT for PTSD: potential for significant improvement, but also a specific, dose-dependent risk of emotional distress. This means that for a significant minority of PTSD patients, high-dose HBOT could temporarily worsen their emotional state, causing distress that, while reversible, is still a genuine concern during treatment.

The studies included in the review covered subjects who were 3-450 months post-trauma, indicating that HBOT was considered for both acute and chronic PTSD cases. The fact that this emotional exacerbation was observed across different timeframes since trauma suggests it is not limited to a specific phase of the disorder. This widespread applicability of the risk underscores the need for universal caution when using high doses in this patient population. The cumulative oxygen doses in these studies ranged from 1002 to 11,400 atmosphere-minutes of oxygen. It was at the upper end of this spectrum that the severe emotional reactions became more prevalent. This suggests that careful titration of oxygen dose, rather than simply aiming for the highest possible dose for maximum benefit, might be a safer approach for many PTSD patients.

Understanding the Mechanism of Risk

While the research highlights the statistical occurrence of emotional exacerbation, it does not fully detail the underlying physiological or psychological mechanisms. However, the observation that the highest doses lead to this effect suggests a potential overstimulation or altered neurochemical response in the brain. The brain imaging changes observed in three of the studies, which correlated with symptomatic improvements, suggest that HBOT does indeed have a direct impact on brain function and anatomy in PTSD-affected regions. This impact, while largely beneficial, could also explain why some individuals experience an adverse emotional reaction at very high oxygen levels. The brain's response to hyperoxia (excess oxygen) can be complex and may vary significantly between individuals, especially those with pre-existing neurological or psychiatric vulnerabilities like PTSD.

Mitigating the Danger

To mitigate the danger for PTSD patients, healthcare providers must adopt a highly individualized approach to HBOT. This involves a thorough pre-treatment assessment to identify potential risk factors, including the severity of PTSD symptoms, co-occurring mental health conditions, and any history of emotional instability. During treatment, close monitoring of the patient's emotional state is crucial. This could involve regular psychological assessments, direct communication with the patient about their feelings, and potentially involving mental health professionals in the treatment team. If emotional exacerbation begins, the HBOT protocol may need to be adjusted, including reducing the oxygen dose or temporarily pausing treatment. The goal is to maximize therapeutic benefit while minimizing the risk of adverse emotional events.

Furthermore, patient education plays a vital role. PTSD patients considering HBOT should be fully informed about the potential for severe, reversible emotional exacerbation, especially at higher doses. Understanding this risk beforehand can help patients prepare for potential emotional fluctuations and feel more comfortable reporting them to their healthcare team. It also allows them to make an informed decision about proceeding with HBOT, particularly if high doses are being considered. The ethical obligation to fully disclose these specific risks is paramount, ensuring that patients are truly partners in their treatment decisions.

Long-Term Implications and Future Research

The finding that PTSD can no longer be considered strictly a psychiatric disease, as indicated by the imaging findings and HBOT effects, opens new avenues for understanding and treating the condition. This reclassification suggests a more complex neurobiological basis for PTSD, which HBOT appears to influence directly. However, it also means that interventions like HBOT, which directly affect brain physiology, must be approached with a deep understanding of their potential side effects on a neurologically vulnerable population. Future research, including the $28 million USF Health state-funded trial launched in 2024-2025, is actively looking at biomarkers that predict which PTSD and TBI patients are most susceptible to emotional exacerbation at high oxygen doses, allowing for even more personalized and safer treatment protocols in the coming years.

Does HBOT pose risks for acute ischemic stroke patients?

For patients suffering from acute ischemic stroke (AIS), hyperbaric oxygen therapy (HBOT) does not appear to pose significant risks in terms of worsening key neurological and functional outcomes, based on a 2024 systematic review and meta-analysis. This comprehensive study, which included eight randomized controlled trials involving 493 patients, aimed to evaluate the efficacy and safety of adjunctive HBOT for AIS. The findings indicated no statistically significant differences between HBOT and control groups in several crucial measures of stroke severity and recovery.

Specifically, the meta-analysis showed no statistically significant differences in the National Institutes of Health Stroke Scale (NIHSS) score (MD = -1.41, 95%CI = -7.41 to 4.58) or the Barthel index (MD = 8.85, 95%CI = -5.84 to 23.54) when comparing HBOT to non-HBOT or sham HBOT treatments. The NIHSS score is a widely used tool to quantify stroke severity, while the Barthel index measures a person's ability to perform daily living activities. The absence of significant differences in these scores suggests that HBOT does not worsen stroke outcomes in these areas. It also implies that HBOT, as an adjunctive therapy, did not provide a statistically significant improvement in these specific measures compared to standard care or sham treatments.

However, the study did report some nuanced findings regarding safety and other outcome measures. While no significant difference was found in adverse event incidence within ≤ 6 months of follow-up (OR = 0.98, 95%CI = 0.25 to 3.79), HBOT did show a significant improvement in the modified Rankin score (MD = 0.10, 95%CI = 0.03 to 0.17). The modified Rankin Scale (mRS) is another measure of disability or dependence in daily activities of people who have experienced a stroke. A statistically significant improvement in mRS suggests some potential benefit in functional recovery, even if NIHSS and Barthel scores did not show the same.

Furthermore, the meta-analysis found that the incidence of adverse events at the end of treatment was actually lower in the HBOT group compared to the control group (OR = 0.42, 95%CI = 0.19 to 0.94). This particular finding suggests that, in the immediate post-treatment period, HBOT might even offer a protective effect against certain adverse events in AIS patients. This is an interesting contrast to the emotional exacerbation seen in some PTSD patients. However, it is important to remember that this reduced adverse event rate did not translate into a statistically significant reduction in adverse events over a longer follow-up period of up to six months.

"A total of 8 studies involving 493 patients were included. The meta-analysis showed no statistically significant differences between HBOT and the control group in terms of NIHSS score (MD = -1.41, 95%CI = -7.41 to 4.58), Barthel index (MD = 8.85, 95%CI = -5.84 to 23.54)... However, HBOT showed significant improvement in modified Rankin score (MD = 0.10, 95%CI = 0.03 to 0.17), and adverse event incidence at the end of treatment (OR = 0.42, 95%CI = 0.19 to 0.94) compared to the control group," explained Xuezheng Li et al. in BMC Neurol. 2024. This detailed statistical breakdown provides concrete evidence for the observed safety and efficacy profile of HBOT in AIS. A February 2026 randomized, double-blind, sham-controlled trial in post-stroke depression has since extended this work, suggesting HBOT may modulate neurotrophic factors during stroke recovery — a mechanism that could eventually help explain the modified Rankin improvement seen in earlier AIS meta-analyses.

Specific Inflammatory Markers and HBOT

Beyond neurological and functional outcomes, the meta-analysis also investigated the impact of HBOT on several inflammatory markers in AIS patients. Inflammation plays a critical role in the pathophysiology of stroke, and modulating it could theoretically improve outcomes. However, the study found no statistically significant differences for a range of inflammatory markers, including TNF-α (MD = -5.78, 95%CI = -19.93 to 8.36), sICAM (MD = -308.47, 95%CI = -844.13 to 13227.19), sVCAM (MD = -122.84, 95%CI = -728.26 to 482.58), sE-selectin (MD = 0.11, 95%CI = -21.86 to 22.08), or CRP (MD = -5.76, 95%CI = -15.02 to 3.51). This indicates that HBOT, as studied in these trials, did not significantly alter these specific inflammatory responses in AIS patients.

This lack of significant impact on inflammatory markers, combined with the largely neutral effect on NIHSS and Barthel scores, suggests that while HBOT may not be actively dangerous for AIS patients, its benefits as an adjunctive treatment for these specific outcomes are not strongly supported by this meta-analysis. The significant improvement in the modified Rankin score is a positive signal, but it needs to be interpreted within the broader context of the other findings.

Limitations and Future Directions

The meta-analysis itself was based on eight studies, involving 493 patients. While this provides a good foundation, the overall number of patients is still relatively modest. Future, larger randomized controlled trials might be able to detect more subtle effects or confirm the trends observed. It is also important to consider the heterogeneity of stroke patients, the timing of HBOT initiation, and the specific HBOT protocols (pressure, duration, number of sessions) used across different studies. These factors can influence outcomes and might explain some of the variability observed.

For now, the evidence suggests that HBOT is largely safe for AIS patients in terms of not exacerbating their condition or increasing adverse events long-term. The finding of a lower adverse event incidence at the end of treatment is a positive safety signal. However, practitioners should be aware that the evidence for significant efficacy in improving major neurological deficits (NIHSS) or activities of daily living (Barthel index) is not yet statistically robust. Decisions regarding HBOT for AIS should therefore be made carefully, considering all available evidence and individual patient circumstances.

Are there ongoing trials addressing HBOT safety for brain injuries?

Yes, there are active and ongoing clinical trials specifically addressing the safety and efficacy of hyperbaric oxygen therapy (HBOT) for brain injuries, particularly traumatic brain injury (TBI). These trials are crucial for expanding our understanding of HBOT's role in complex neurological conditions and for further evaluating its safety profile in this patient population. One such prominent trial is the "Hyperbaric Oxygen Brain Injury Treatment Trial," registered as NCT02407028 on ClinicalTrials.gov. This trial is designed to rigorously test whether HBOT can help reduce symptoms after traumatic brain injury. Alongside it, a newer $28 million state-funded trial based at USF Health launched its first participants in 2024-2025 and now ranks among the most rigorous HBOT-TBI studies in the country, targeting Florida service members and veterans specifically.

The Hyperbaric Oxygen Brain Injury Treatment Trial (NCT02407028) is a randomized clinical trial that compares the effects of HBOT to an inactive (or placebo) HBOT. This design is considered the gold standard for clinical research, as it helps to isolate the true effects of the treatment by controlling for placebo effects. The primary objective is to determine if HBOT can effectively reduce the persistent symptoms that often follow a traumatic brain injury or concussion. This trial is particularly focused on a specific demographic: U.S. Service Members and Veterans. This focus is important because military personnel often experience TBIs in combat or training, leading to unique challenges and symptom profiles.

The eligibility criteria for participating in this trial are quite specific. Participants must be U.S. Service Members or Veterans, aged 18-75 years. A key medical criterion is that they must have experienced a mild or moderate traumatic brain injury or concussion exposure at least one year prior to enrollment. This ensures that the trial is studying persistent post-concussion symptoms rather than acute injury responses, which might have different treatment considerations. The requirement for the injury to have occurred at least one year prior suggests that the trial is looking at chronic effects and long-term recovery, which is a significant area of need for TBI patients. ClinicalTrials.gov HBOT Brain Injury Treatment Trial clearly lists these details. For more details, see HBOT safety in acute ischemic stroke 2024 meta-analysis.

The trial is anticipated to last approximately 4 months for each participant, covering the treatment period and follow-up. This duration allows for sufficient time to observe any changes in symptoms and to assess the sustained effects of HBOT. The rigorous methodology of a randomized clinical trial, including the use of a placebo group, is essential for generating high-quality evidence that can inform clinical practice and policy. Such trials are instrumental in not only determining efficacy but also in meticulously documenting any adverse events or safety concerns that arise during the treatment period.

Importance of Randomized Controlled Trials

Randomized controlled trials (RCTs) like NCT02407028 are vital for understanding HBOT safety. By comparing an active treatment to a placebo, researchers can distinguish between actual treatment effects and psychological or spontaneous recovery effects. This is particularly important for conditions like TBI, where symptoms can fluctuate and recovery pathways are complex. The detailed monitoring of participants in an RCT allows for the systematic collection of safety data, including any adverse events, their severity, and their relationship to the HBOT intervention. This data is then used to build a comprehensive safety profile for HBOT in the context of TBI.

The fact that this trial accepts healthy volunteers as a type of eligibility criteria indicates a broader approach to understanding the effects of HBOT, potentially allowing for comparison points or baseline data that can further contextualize findings from the TBI group. However, the primary focus remains on individuals with a history of brain injury. The study details on ClinicalTrials.gov emphasize the importance of data element definitions for study record managers, highlighting the meticulous nature of data collection and reporting in such trials.

Addressing Specific Safety Concerns in TBI

For TBI patients, specific safety concerns related to HBOT include potential effects on intracranial pressure, seizure risk in patients with post-traumatic epilepsy, and complications related to existing neurological deficits or shunt hardware. The 2025-2026 FDA Letter to Health Care Providers reiterated that device-related injuries and deaths continue to occur in unregulated settings, with fire risk and failure to follow device labeling as the top contributors. That is precisely why UHMS accreditation and NCT02407028's careful inclusion criteria matter: participants must tolerate a test compression before randomization, which screens out many barotrauma-prone patients before any treatment begins. The trial's focus on persistent symptoms also implies that participants may have underlying chronic neurological changes, making the assessment of HBOT safety even more critical.

The information for healthcare providers provided on the USF HBOT website (hbot.usf.edu) further indicates the professional and medical context of this research. USF Health's separate $28 million state-funded trial, announced publicly in 2024 and now actively enrolling, is explicitly designed to feed long-term safety and efficacy data back into the national evidence base for HBOT in neurological disease. The trial's inclusion of a broad age range (18-75 years) also ensures that the findings will be relevant to a wide demographic of TBI survivors, from young adults to older veterans.

In summary, the Hyperbaric Oxygen Brain Injury Treatment Trial (NCT02407028), now running in parallel with USF Health's state-funded TBI trial, represents a crucial effort to understand the safety and effectiveness of HBOT for chronic TBI symptoms. Their rigorous designs, focus on a specific and highly affected population (U.S. Service Members and Veterans), and careful monitoring will contribute significantly to the evidence base for HBOT, helping to clarify when it is a safe and beneficial treatment option for brain injuries and when potential risks might outweigh the benefits. This ongoing research is vital for providing concrete, evidence-based guidance for clinicians and patients alike.

What did the systematic review on PTSD reveal about HBOT safety?

The systematic review on hyperbaric oxygen therapy (HBOT) for posttraumatic stress disorder (PTSD), published in 2024, revealed critical insights into both the efficacy and safety profile of the treatment. This comprehensive review included eight studies, all of which focused on adult clinical populations and were published in English. The total number of subjects across these studies was 393, with each individual study involving fewer than 75 participants. This relatively small number of subjects per study, while still yielding significant findings, highlights the need for continued research with larger cohorts.

A key finding related to safety was the observation that the highest oxygen doses administered during HBOT were associated with a significant adverse effect: a severe, but reversible, exacerbation of emotional symptoms. This specific reaction occurred in 30-39% of subjects receiving these high doses. While the exacerbation was temporary, its severity indicates a genuine concern for patient well-being during treatment. This finding underscores the importance of careful dose management and close monitoring of patients, particularly their emotional state, throughout the course of HBOT for PTSD. Other side effects reported in these studies were generally classified as transient and minor, suggesting that the most significant safety concern in this context is the emotional response to high oxygen levels.

The review also provided a detailed look at the methodology and quality of the included studies. Seven of the eight studies were randomized trials, and one was an imaging case-controlled study. A majority of the studies, six, focused exclusively on military subjects, one included both civilian and military subjects, and one was solely on civilians. This demographic breakdown suggests that much of the evidence for HBOT in PTSD comes from military populations, which may have specific types of trauma and co-morbidities. The methodological quality of the randomized trials was assessed using the PEDro Scale, and all seven randomized trials were found to be of good-highest quality. This high quality rating lends credibility to the findings regarding both efficacy and safety.

The subjects in these studies were diverse in terms of their time since trauma, ranging from 3 to 450 months post-trauma. This broad range indicates that HBOT was investigated for both relatively recent and long-standing PTSD symptoms. Statistically significant symptomatic improvements were achieved with 40-60 HBOT sessions, utilizing pressures from 1.3 to 2.0 ATA. A linear dose-response relationship was identified, meaning that greater symptomatic improvement correlated with increasing cumulative oxygen doses, ranging from 1002 to 11,400 atmosphere-minutes of oxygen. However, it was at the higher end of this dose spectrum that the severe emotional exacerbations were more frequently observed.

Correlative Brain Imaging Changes

An important aspect of the systematic review was the inclusion of studies that examined brain imaging changes. In three of the included studies, the symptomatic improvements observed with HBOT were associated with functional and anatomic brain imaging changes. These findings are significant because they provide objective, biological evidence supporting the therapeutic effects of HBOT on the brain. The correlation between symptomatic improvements and changes in PTSD-affected brain regions suggests that HBOT is not merely addressing psychological symptoms but is influencing the underlying neurological substrates of the disorder.

"The imaging findings and hyperbaric oxygen therapy effects indicate that PTSD can no longer be considered strictly a psychiatric disease," stated Susan R Andrews et al. This powerful statement from the researchers highlights a paradigm shift in understanding PTSD. If HBOT can induce measurable changes in brain structure and function that correlate with symptom reduction, it suggests a more complex neurobiological component to PTSD than previously thought. This reclassification has profound implications for how PTSD is diagnosed, understood, and treated, moving it beyond a purely psychological framework.

Implications for Clinical Practice

For clinicians, the systematic review offers clear guidance. HBOT can be an effective treatment for PTSD, leading to statistically significant improvements. However, the risk of severe, reversible emotional exacerbation at high oxygen doses cannot be ignored. This means that personalized treatment plans, careful patient selection, and vigilant monitoring of emotional well-being are essential when administering HBOT for PTSD. Starting with lower doses and gradually increasing them while closely observing the patient's response may be a prudent strategy to mitigate the risk of adverse emotional reactions.

The review emphasizes that while HBOT offers promise, its application requires a nuanced understanding of its potential side effects, particularly the emotional ones. The transient and minor nature of other side effects is reassuring, but the unique psychological vulnerability of PTSD patients to high oxygen doses warrants specific attention. Future research could focus on identifying predictors of this emotional exacerbation, allowing for even more refined patient selection and individualized dosing strategies.

How does HBOT affect inflammatory markers in acute ischemic stroke?

When examining the impact of hyperbaric oxygen therapy (HBOT) on acute ischemic stroke (AIS) patients, a 2024 systematic review and meta-analysis specifically investigated its effects on various inflammatory markers. Inflammation is a critical process in the brain after a stroke, contributing to secondary brain damage and influencing recovery outcomes. Modulating this inflammatory response could theoretically be a mechanism through which HBOT might exert therapeutic effects. However, the findings from this meta-analysis indicated that HBOT did not significantly alter the levels of several key inflammatory markers.

The meta-analysis included eight studies involving 493 patients with AIS. Researchers looked at the impact of HBOT on markers such as Tumor Necrosis Factor-alpha (TNF-α), soluble Intercellular Adhesion Molecule-1 (sICAM), soluble Vascular Cell Adhesion Molecule-1 (sVCAM), soluble E-selectin, and C-reactive protein (CRP). These markers are commonly associated with inflammatory processes and endothelial activation, which are relevant in the context of ischemic stroke pathophysiology.

The results showed no statistically significant differences between the HBOT group and the control group for any of these inflammatory markers. For instance, the mean difference (MD) for TNF-α was -5.78 (95%CI = -19.93 to 8.36), indicating no significant change. Similarly, for CRP, the MD was -5.76 (95%CI = -15.02 to 3.51), again showing no statistically significant effect. The other markers, sICAM, sVCAM, and sE-selectin, also failed to demonstrate any statistically significant differences between the two groups.

This consistent lack of significant change across multiple inflammatory markers suggests that, based on the evidence reviewed in this meta-analysis, adjunctive HBOT for AIS does not exert a substantial modulatory effect on these specific inflammatory pathways. While HBOT is known to have anti-inflammatory properties in other contexts, this specific application in AIS, as studied in these trials, did not lead to measurable differences in the selected inflammatory biomarkers. This implies that if HBOT does confer benefits in AIS, it might be through other mechanisms, such as enhancing oxygen delivery to ischemic penumbra, reducing oxidative stress, or promoting neuroplasticity, rather than directly suppressing the systemic inflammatory response as reflected by these markers.

Interpreting the Lack of Effect

The absence of a statistically significant effect on inflammatory markers is an important finding for several reasons. Firstly, it helps to refine our understanding of HBOT's potential mechanisms of action in AIS. If inflammation modulation is not a primary pathway for benefit, then research and clinical focus can shift to other areas. Secondly, it suggests that HBOT, at the protocols used in these studies, does not worsen inflammation, which would have been a significant safety concern. The fact that levels remained similar to the control group indicates a neutral impact rather than a detrimental one.

It is worth noting that the meta-analysis did find a significant improvement in the modified Rankin score for HBOT patients (MD = 0.10, 95%CI = 0.03 to 0.17) and a lower incidence of adverse events at the end of treatment (OR = 0.42, 95%CI = 0.19 to 0.94). These positive findings, in the absence of significant changes in inflammatory markers, could point to HBOT influencing recovery through pathways other than the direct suppression of systemic inflammation as measured by these specific markers. For example, HBOT's ability to increase oxygen tension in compromised brain tissue could prevent further cell death and support neuronal survival, leading to better functional outcomes without necessarily altering systemic inflammatory mediators.

Future Research Directions

Future research could explore a broader range of inflammatory and immune markers, including those specific to the central nervous system, which might be more directly affected by HBOT. It is possible that the systemic markers measured in these studies do not fully capture localized inflammatory changes within the brain. Additionally, the timing and duration of HBOT administration relative to stroke onset could influence its effects on inflammation. Different HBOT protocols (e.g., higher pressures, more frequent sessions) might also yield different results.

The current evidence, however, suggests that for AIS patients, HBOT does not significantly impact the measured inflammatory markers. This means that while HBOT might be considered safe in this regard, its potential benefits are likely mediated through non-inflammatory pathways. Clinicians should consider this when evaluating the overall profile of HBOT for acute ischemic stroke, focusing on the observed functional and safety outcomes rather than expecting significant changes in these specific inflammatory biomarkers. The data from Li et al., 2024, provides a clear picture that HBOT's role in AIS safety and efficacy, while showing some positive signals in functional recovery and immediate adverse events, does not extend to a significant modulation of the commonly assessed inflammatory markers.

2026 FDA Clearances, Pricing, and Regulatory Updates

The regulatory landscape around HBOT has shifted noticeably in 2025-2026, and these changes directly affect who can safely access the therapy and at what cost. Understanding the updated rules is part of any honest discussion about when HBOT becomes genuinely dangerous — because danger in this field often comes not from the oxygen itself, but from off-label use in unaccredited facilities.

Updated FDA Cleared Indications

HBOT devices are regulated as Class II medical devices, cleared through the FDA's 510(k) process under product code CBF. In 2025-2026, the FDA added two new conditions to its cleared-use list, bringing the total to 14 approved indications. The new additions are (1) sudden sensorineural hearing loss of unknown cause and (2) sudden painless vision loss in one eye due to central retinal artery occlusion. These additions reflect growing evidence for time-sensitive emergency use, but they also narrow the gap between "cleared" and "off-label" — meaning clinics offering HBOT for conditions like autism, long COVID, anti-aging, or general wellness continue to operate in off-label territory, which the FDA explicitly flags as higher risk. See the sudden sensorineural hearing loss evidence atlas for the full study-by-study evidence breakdown.

The FDA's 2025-2026 Letter to Health Care Providers reiterates that the agency is aware of serious injuries and deaths associated with HBOT devices, with fire the single highest-impact hazard. Low-pressure fabric chambers (so-called "mild HBOT" or mHBOT) are not designed for supplemental oxygen use above 1.4 ATA, and the UHMS, AMA, and FDA have all publicly flagged that combining concentrated oxygen with soft-shell chambers designed for ambient air is genuinely dangerous. If you are evaluating a clinic, look for UHMS accreditation; the FDA now openly recommends UHMS-accredited facilities for specific illness treatment.

2026 Pricing Reality Check

HBOT pricing in 2026 is highly bimodal, which matters because price often correlates with the safety infrastructure behind the chamber:

Soft-chamber clinic sessions: $75 to $400 per session for mild HBOT at wellness centers and biohacking studios, with package pricing often dropping the per-session rate on 10-40 session bundles.
Hard-chamber clinic sessions: $200 to $600 per session at standalone hyperbaric clinics operating at 1.5-2.0 ATA with medical-grade oxygen.
Hospital-based medical HBOT: Commonly over $2,000 per session, with some facility-fee-heavy markets exceeding $3,000 per session for on-label treatments like diabetic foot ulcers, osteoradionecrosis, or carbon monoxide poisoning.
Home chambers: Soft-shell models range from $5,000 to $20,000, while hard-shell residential units run $30,000 to $150,000+ and require professional installation plus ongoing maintenance.
Medicare Part B covers approximately 80% of the Medicare-approved amount for on-label HBOT conditions in 2026, with patients responsible for the remaining 20% coinsurance after the $283 Part B deductible.

Market Growth and What It Means for Safety

The global HBOT market is projected to expand by $177.6 million between 2026 and 2030, growing at a roughly 6.0% CAGR. Rapid market growth brings more providers into the space, and not all of them operate at UHMS-accredited safety standards. If a facility is not UHMS accredited, is running at pressures or oxygen concentrations outside its device's labeling, or is marketing for off-label indications without medical oversight, the probability of a genuinely dangerous outcome goes up — often dramatically.

Frequently Asked Questions

What are the most common side effects of HBOT?

The most common side effects of HBOT are transient and minor, typically ear and sinus barotrauma from pressure changes, temporary myopic shifts in vision that resolve within days to weeks, and mild fatigue or claustrophobia during sessions. For specific conditions like PTSD, a significant side effect can be severe, reversible exacerbation of emotional symptoms, observed in 30-39% of subjects at the highest oxygen doses. More serious complications are rare but include oxygen toxicity seizures, pulmonary oxygen toxicity, and (in inadequate facilities) chamber fires. For acute ischemic stroke, the incidence of adverse events at the end of treatment was actually lower in the HBOT group (OR = 0.42, 95%CI = 0.19 to 0.94) compared to controls.

Can HBOT worsen psychiatric symptoms?

Yes, HBOT can potentially worsen psychiatric symptoms, particularly emotional ones, in patients with PTSD. A 2024 systematic review found that 30-39% of subjects treated for PTSD experienced a severe, reversible exacerbation of emotional symptoms when exposed to the highest oxygen doses. The effect is strongly dose-dependent, emerging at cumulative exposures near the upper end of the 1002-11,400 atmosphere-minute range studied. Clinicians managing PTSD with HBOT in 2026 increasingly start lower and titrate up, watching for mood shifts between sessions and involving mental health professionals as part of the treatment team. This highlights a specific risk for this patient population, emphasizing the need for careful dosage and monitoring.

Is HBOT effective for acute ischemic stroke?

The efficacy of HBOT for acute ischemic stroke is mixed. A 2024 meta-analysis of 8 trials and 493 patients found no statistically significant differences in NIHSS score (MD = -1.41, 95%CI = -7.41 to 4.58) or Barthel index. However, HBOT did show a significant improvement in modified Rankin score (MD = 0.10, 95%CI = 0.03 to 0.17), suggesting some potential benefit in functional recovery, though not necessarily in initial stroke severity or daily living activities. A February 2026 randomized sham-controlled trial also found HBOT may upregulate neurotrophic factors in post-stroke depression, pointing to a biological mechanism behind the mRS improvement. Most stroke neurologists still treat HBOT as experimental for AIS pending larger RCTs.

Are there ongoing studies for HBOT in traumatic brain injury?

Yes, there are ongoing clinical trials addressing HBOT for traumatic brain injury (TBI). The federal NCT02407028 is a randomized study testing whether HBOT can reduce symptoms after TBI compared to a placebo chamber, enrolling U.S. Service Members and Veterans aged 18-75 who experienced mild or moderate TBI or concussion at least one year prior. Running alongside it, USF Health launched a $28 million state-funded trial in 2024-2025 for Florida service members and veterans with TBI, now recognized as one of the most rigorous HBOT-TBI studies in the country. Together, these trials are expected to produce long-term safety and efficacy data that could meaningfully reshape HBOT's role in neurological disease over the next several years.

What kind of studies support the risks and benefits of HBOT?

The risks and benefits of HBOT are supported by various types of studies, including systematic reviews and meta-analyses of randomized controlled trials (RCTs). For instance, a 2024 systematic review on PTSD included eight studies, seven of which were RCTs, all rated of good-highest quality by the PEDro Scale. A 2024 meta-analysis on acute ischemic stroke also combined data from eight RCTs involving 493 patients. A clinically focused 2026 review in CA: A Cancer Journal for Clinicians addresses HBOT for chronic radiotherapy-related adverse effects, and new 2024-2026 work on long COVID, post-stroke depression, and TBI continues to expand the evidence base. Regulatory context comes from the FDA's 2025-2026 safety communications and UHMS accreditation guidance, which together define what "safe HBOT" looks like in practice.

Is mild HBOT (soft-shell chamber) dangerous?

Mild HBOT can be genuinely dangerous when used outside its labeling. Soft-shell fabric chambers are cleared only for acute mountain sickness at pressures up to 1.4 ATA with ambient air, not concentrated oxygen. The UHMS, AMA, and FDA have all publicly warned that pressurizing soft chambers above 1.4 ATA, or combining them with supplemental oxygen, creates fire and barotrauma risk the devices were never designed to handle. In 2025-2026, the FDA renewed its Letter to Health Care Providers specifically about following device instructions. If a clinic is running a soft chamber on 90%+ oxygen at higher pressures, that is an off-label, higher-risk setup and worth declining.

How much does HBOT cost in 2026?

HBOT pricing in 2026 spans a wide range depending on chamber type and setting. Soft-chamber wellness sessions run $75 to $400, hard-chamber clinic sessions $200 to $600, and hospital-based medical HBOT commonly exceeds $2,000 per session, with some markets over $3,000. Home soft-shell chambers cost $5,000 to $20,000, while hard-shell residential units run $30,000 to $150,000+ and require professional installation. Medicare Part B covers about 80% of the approved amount for on-label conditions after the 2026 Part B deductible of $283; private insurance typically follows Medicare's on-label list. Off-label indications (long COVID, anti-aging, autism, general wellness) are almost always out-of-pocket.